- Study of the protective *OAS1* rs10774671-G allele against severe
- COVID-19 in Moroccans suggests a North African origin for 2
- **Neanderthals** 3

4

8 9

- Fatima Zohra El Youssfi¹, Abbas Ermilo Haroun^{2,3}, Chaimae Nebhani¹, Jihane 5
- Belayachi^{2,4}, Omar Askander⁵, Elmostafa El Fahime⁶, Hakima Fares⁷, Khalid Ennibi⁸, 6
- 7 Redouane Abougal^{2,3}, Rachid Razine^{2,3}, Ahmed Bouhouche^{1,9*}
- 10 1 Laboratory of Human Genetics, Medical School and Pharmacy, University Mohammed V in Rabat,
- 11 Morocco
- 12 2 Laboratory of Biostatistics, Clinical and Epidemiological Research, Department of Public Health,
- 13 Medical School and Pharmacy, University Mohammed V in Rabat, Morocco
- 14 3 Laboratory of Community Health, Department of Public Health, Medical School and Pharmacy,
- 15 University Mohammed V in Rabat, Morocco
- 16 4 Acute Medical Unit, Ibn Sina University Hospital, Rabat, Morocco
- 17 5 Faculty of Medical Science, Mohammed VI Polytechnic University, Benguerir, Morocco.
- 18 6 Molecular Biology and Functional Genomics Platform, National Center for Scientific and Technical
- 19 Research, Rabat, Morocco.
- 20 7 Intensive Care Department, Cheikh Zaid International Universitary Hospital, Rabat, Morocco
- 21 8 Virology, Infectious and Tropical Diseases Center, Hôpital Militaire d'Instruction Mohammed V.
- 22 Rabat.

25

26

27

- 23 9 Genomic Center of the Cheikh Zaid Foundation, Abulcasis International University of Health
- 24 Sciences, Rabat, Morocco

- 28 * Correspondence author
- 29 E-mail: a.bouhouche@um5r.ac.ma (AB)
- WATE: This preprint reports: new research that has not been certified by peer review and should not be used to guide clinical practice. https://orcid.org/0000-0001-32/9-8049 30

Abstract

31

52

Background: The clinical presentation of COVID-19 has shown high variability 32 between individuals, which is partly due to genetic factors. The OAS1/2/3 cluster 33 was found to be strongly associated with COVID-19 severity. We aimed to 34 examine this locus for the occurrence of the critical variant, rs10774671, and its 35 respective haplotype blocks within the Moroccan population. 36 37 **Methods**: The frequency of SNPs at the cluster of OAS immunity genes was assessed from an in-house database in 157 unrelated individuals of Moroccan 38 origin. The OASI exon 6 was sequenced by Sanger's method in 71 39 asymptomatic/mild and 74 moderate/severe individuals positive for SARS-CoV-40 2. Genotypic, allelic, and haplotype frequencies of three SNPs were compared 41 42 between the two groups. Finally, males in our COVID-19 series were genotyped for the Berber-specific marker E-M81. 43 **Results**: The prevalence of the *OASI* rs10774671-G allele in present-day 44 Moroccans was 40.4%, close to that of Europeans. However, it was found equally 45 on both the Neanderthal GGG haplotype and the African GAC haplotype with a 46 frequency of 20% each. These two haplotypes, and hence the rs10774671-G 47 allele, were significantly associated with the protection against severe COVID-19 48 (p = 0.034, p = 0.041, and p = 0.008 respectively). Surprisingly, among Berber 49 men, the African haplotype was absent while the prevalence of the Neanderthal 50 haplotype was close to that of Europeans. 51

Conclusion: The protective rs10774671-G allele of *OAS1* was found only in the

Neanderthal haplotype in Berbers, the indigenous people of North Africa, suggesting that this region may have served as the stepping-stone for the passage of the hominids to the other continents. **Keywords:** SARS-CoV-2, COVID-19 severity, 2',5'-oligoadenylate synthetase, single nucleotide polymorphism, Neanderthals, North Africa

1. Introduction

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

COVID-19, caused by the coronavirus SARS-CoV-2, appeared in November 2019 in Wuhan, Hubei province (China), before spreading around the world and causing a pandemic [1, 2]. The consequences of SARS-CoV-2 infection vary greatly from person to person and from population to population. While most infected individuals are asymptomatic or minimally symptomatic, some develop severe or even critical illness. Older people and those with underlying medical condition, such as cardiovascular disease, diabetes, chronic respiratory disease, or cancer, are at greater risk of developing a severe form [3]. However, these risk factors alone do not explain the variability in severity observed. These differences could partly result from individual genetic susceptibility. The scientific community has been mobilized to respond to the health crisis to identify the genetic determinants of COVID-19 that protect people from or predispose them to severe manifestations of the disease. A genetic study conducted on patients of European ancestry identified a risk locus for severe COVID-19 in the 2'-5'oligoadenylate synthetase 1/2/3 (OAS1/2/3) gene cluster [4]. Subsequently, it was reported that elevated levels of OAS1 in the plasma were associated with reduced COVID-19 susceptibility and severity [5]. This genetic region of chromosome 12q24.13 carries a haplotype of approximately 75 kb of Neanderthal origin [6], where the discovery of the causal variant was possible through studies conducted on a multiancestry cohort including patients from both African and European ancestry. It consists of rs10774671 with G>A transition occurring at a splice acceptor site, where the protective ancestral G allele produces a longer OAS1 transcript and a more active protein [7, 8]. Moreover, OASI SNPs have been reported to be associated with susceptibility to West Nile virus infections [9] and to be involved in altered cellular function leading to several autoimmune and infectious diseases, suggesting that the OAS genes play a critical role in the innate immune response to viruses [10-14]. For instance, the OAS1 enzyme catalyzes the synthesis of short polyadenylates, which activate ribonuclease L contributing to the degradation of viral RNA and inhibition of viral replication [15, 16]. It produces five transcripts including p42, p44, p46, p48, and p52, and its expression is stimulated by the interferon system [17, 18]. In this study, we assessed the prevalence of several variants at the OAS gene cluster that comprise the Neanderthal haplotype by analyzing exome data of 157 unrelated Moroccan individuals and observed that the *OAS1* rs10774671-G allele was found on both Neanderthal and African haplotypes. We then investigated the rs10774671 variant in 146 Moroccan volunteers positive for SARS-CoV-2 infection and showed that it was significantly associated with COVID-19 severity. Interestingly, in Berbers of both paternal and maternal lineages, the African haplotype containing the G allele was absent while the frequency of Neanderthalderived haplotypes is close to that of Europeans.

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

Material and methods

Frequency of *OAS* gene variants in the Moroccan population

To assess the frequency in the Moroccan population of the Neanderthal haplotype at the cluster of *OAS* immunity genes in the chromosomal region 12q24.13, we analyzed exome data from 157 unrelated patients suspected of having a rare hereditary disease. These patients were recruited from the Department of Neurology of Specialties Hospital and Cheikh Zaid Hospital of Rabat. Part of the data was taken from the in-house exome database and the other part comes from whole exome sequencing (WES) carried out as part of a collaborative project with 3Billion® (Seoul, Korea). Data were collected for variants rs1131454, rs10774671, rs1131476, rs1051042 and rs2660 in *OAS1*, rs1859330, rs1859329 and rs2285932 in *OAS3*, and the variant rs1293767 in *OAS2*, variants that comprise the Neanderthal haplotype at the *OAS* locus as described elsewhere [19].

COVID-19 Patients recruitment

To highlight whether the variants studied are associated with the severity of COVID-19 in the Moroccan population, it was essential to minimize the effects of underlying medical conditions such as comorbidities by reducing the upper age limit of patients. Thus, we have adopted the selection criteria including males or females of Moroccan origin, aged between 18 and 65 years old, with positive RT-PCR test for SARS-COV-2, who have not received any vaccines. Pregnant patients were excluded from the study. 146 COVID-19 patients were enrolled for

1 year between 28 July 2020 to 15 July 2021, a period of the pandemic dominated by the alpha and beta variants. All patients filled out a form concerning sociodemographic data for the establishment of ethnicity and medical history, notifying comorbidities, if applicable. Patients were recruited by three different hospital centers involved in a national COVID-19 research consortium, including the Medical Emergency Department (CHU Ibn Sina, Rabat), the Virology Department (Military Hospital, Rabat), and the Intensive Care Unit (Cheikh Zaid international university hospital, Rabat). Outcomes were defined as asymptomatic (without symptoms), mild (non-hospitalized), moderate (hospitalized but not requiring invasive ventilation), and severe (hospitalized requiring invasive ventilation or death). 146 patients were recruited and grouped into the following severity categories, asymptomatic (N = 21), mild COVID-19 (N = 50), moderate COVID-19 (N = 48), and severe COVID-19 (N = 27). Asymptomatic and mild patients were grouped (N=71) and compared to moderate/severe patients (N=75). Five ml of venous blood was collected in an EDTA tube from each participant and stored at -20°C until DNA extraction. The written informed consent was signed by all patients before their enrollment. This study was approved by the ethics committee of Cheikh Zaid Hospital of Rabat (ID: CEFCZ/AB/PR RFG).

Genetic analysis

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

Genomic DNA (gDNA) of 146 SARS-CoV-2 positive volunteers was extracted using the MagPurix® Blood DNA Extraction Kit with a Zinexts MagPurix EVO

24 CE IVD system (Zinexts Life Science Corp., New Taipei City, Taiwan). Quality and concentrations of DNA samples were analyzed by Nanodrop One^c Spectrophotometer (Thermo Fisher Scientific). PCR amplification, covering the OASI exon 6 and its intron boundaries, was performed using two pairs of specific primers (forward: 5'-GTGGCCAGGCTTCTATACCC-3'; and reverse: 5'-TGGAGTGTGCTGGGTCTATG-3') designed with Primer3 Input (V 0.4.0). PCR amplification was performed using 100 ng of template gDNA, 1 µL of each primer (10 µM), 5 µL of 5X MyTag reaction buffer, and 0.2 µl of MyTag DNA polymerase (Bioline) in a total reaction volume of 25 µL. Thermal conditions were as follows: 95°C for 3 min, 35 cycles of 95°C for 5 sec, 60°C for 15 sec, and 72°C for 10 sec, with a final extension of 72°C for 10 min. The PCR products were visualized by 1.5% agarose gel electrophoresis. Five microliters of PCR amplicons were purified using ExoSap IT-express reagent and 2 microliters of the product were used for cycle sequencing with BigDyeTM Terminator v3.1 Ready Reaction Cycle Sequencing Kit. Electrophoresis was performed on SegStudio Genetic Analyzer, and Sequence data were analyzed by SeqScape 4 software (Thermo Fisher Scientific). The genetic marker, E-M81, reported as being the specific male lineage of autochthonous Berbers of North Africa, was analyzed in all 80 males in the COVID-19 positive cohort of patients. The marker was amplified by PCR and Sanger sequenced as described previously [20].

183

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

Statistical analysis

Statistical analysis was performed using *jamovi* software (Version 1.6). The evaluation of demographic variables and disease characteristics was done using descriptive statistics. A chi-square ($\chi 2$) test was used before the association tests to assess deviation from Hardy-Weinberg equilibrium (HWE) in the control group. The genotypic and allelic frequencies were compared between patients and controls to check the associations of the studied SNPs with COVID-19 severity. The $\chi 2$ test was used to identify the differences in genotypic distribution between study groups under an additive genetic model. For allelic and haplotype models, Odds ratios (ORs) at 95% confidence intervals (CI) were estimated using logistic regression analysis, and p-values less than 0.05 was considered statistically significant.

Results

Frequency of Neanderthal alleles at *OAS* gene cluster in Moroccans

The genotype of 9 SNPs at the cluster of *OAS* immunity genes in the chromosomal region 12q24.13 (Fig 1) was extracted from an exome sequencing database of 157 unrelated individuals, all of Moroccan origin. The results presented in Table 1 showed that, overall, the frequencies of these SNPs in Moroccans are close to the frequency of the minor allele frequency (MAF) of the 1000 genome project. Focusing on *OAS1* variants, the reference G allele of the *OAS1* splice variant rs10774671 represented 40.4% in analyzed Moroccan individuals, close to that of

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

Europeans with 35.2%, but much lower than that of Africans with 64.0% and much higher than that of Asians with only 27.2%. The frequencies of the missense variants rs1131476 and rs1051042, and the 3'UTR rs2660 variant were 21.1% identical, indicating that they are in complete linkage disequilibrium, which was also the case in the other populations of European, Asian and African ancestry (Table 1). Fig 1: OAS gene cluster at chromosome 12q24.13 and structural organization of OAS1 giving the location of the splice variant rs10774671 We then explored the haplotypes formed by the three SNPs rs10774671, rs1131476, and rs1051042, which allowed for identification of the predominantly protective Neanderthal-derived haplotype in this genetic region. The haplotypes consisting of these three SNPs were GGG, GAC, and AAC, and the graphical representation of their distribution in the present-day Moroccans in comparison with different ancestries are shown in Fig 2. The OASI rs10774671-G allele in Moroccans was included in both Neanderthal GGG and African GAC haplotypes with frequencies of 21% and 19.4% respectively. In comparison to other ancestries, the GGG haplotype accounts for 34.5% of Europeans, 27.1% of Asians, and only 2.7% of Africans. The GAC haplotype is however predominant in Africans with a frequency of 61.3% and is almost absent in Europeans and Asians with 0.7% and 0.001% respectively. Finally, the risk haplotype AAC was the prevalent haplotype in the Asian population with 72.4% (Table 1).

Table 1: SNP Frequencies of the OAS locus in 157 individuals of Moroccan origin in comparison with those of the 1000 genomes project

			OAS3			OAS2			
	rs1131454	rs10774671	rs1131476	rs1051042	rs2660	rs1859330	rs1859329	rs2285932	rs1293767
	c.484G>A	c.1039-1G>A	c.1054G>A	c.1082G>C	c.*84G>A	c.53G>A	c.117C>T	c.1314T>C	c.448+41C>G
	p.Gly162Ser	Splice site	p.Ala352Pro	p.Arg361Met	3'UTR	p.Arg18Lys	p.Ala39=	p.lle438=	Intronic
Minor allele frequency	0. 470	0.390	0.210	0.210	0.210	0.340	0.210	0.160	0.150
African Ancestry	0. 851	0.640	0.027	0.027	0.027	0.446	0.011	0.010	0.011
Asian Ancestry	0.414	0.272	0.271	0.271	0.271	0.268	0.268	0.156	0.130
European Ancestry	0.425	0.352	0.345	0.345	0.345	0.370	0.365	0.328	0.325
Moroccan population	0.554	0.404	0.210	0.210	0.210	0.283	0.213	0.197	0.194

Fig 2. Prevalence of the three possible haplotypes with the three OAS1 SNPs studied in 157

individuals of Moroccan origin in comparison with the data of 1000 Genome Project of

Africans, Asians and Europeans.

229

230

232

233

Association study in Moroccan COVID-19 patients

The demographic and clinical data of the two studied groups are shown in Table 234 2. The mean age and standard deviation of patients asymptomatic/mild were 44.1 235 \pm 13.5 years and significantly lower than that of moderate/severe with 51.4 \pm 10.5 236 years (p < 0.001). There was no significant difference regarding the sex ratio 237 between the two groups (OR = 1.04, p < 0.897), with a female-to-male ratio of 238 approximately 1:1. As expected, the patients in the asymptomatic/mild group 239 displayed a significantly lower frequency of comorbidity compared to the 240 moderate/severe group (OR = 2.85, p < 0.004), with 22.5% and 56%, respectively. 241 Likewise, the mortality rate was 0% among the asymptomatic/mild patients and 242 8% among moderate/severe patients, which was significantly different (OR = 243 0.07, p < 0.015). 244 The distribution of genotypes, alleles, and haplotypes of the three OASI SNPs 245 according to severity were presented in Table 3. Among the 292 alleles analyzed, 246 the ancestral G allele represented 40% for the rs10774671variant and 21.23% for 247 both the rs1131476 and rs1051042 variants. The comparison between the two 248 groups studied, asymptomatic/mild versus moderate/severe, shows a significant 249 250 difference under both the additive (p = 0.014) and allelic models (OR 0.528 [95%] CI 0.329-0.848], p = 0.008). However, no statistically significant differences in 251

Table 2: Demographic criteria of COVID-19 studied groups

		Diseas	OR (CI 95%)	<i>p</i> value		
	Asymptomatic/Mild (n = 71)				Moderate/Severe (n = 75)	
	No	%	No	%		
Age (y) Mean ± SD	44.1	+ 13.5	51.4	+ 10.5		< .001
Sex						
Male	39	54.9	41	54.7	1.04 (0.544-2.01)	0.897
Female	32	45.1	34	45.3		
Comorbidity	16	22.5	42	56.0	2.85 (1.39-5.85)	0.004
Mortality	00	0.0	06	8.0	0.07 (0.004-1.35)	0.015

Table 3. Comparison of genotypic and allelic distribution of the OAS1 rs10774671 and rs11314476 SNPs between COVID-19 asymptomatic/mild and Moderate/Severe groups.

SNP	Genetic Model		Asymptomatic/Mild (N= 71)		Moderate /Severe $(N = 75)$		p	OR (95% CI)
				%	N	%		
rs10774671		GG	18	25.3	06	08.0		
	Additive model	GA	32	45.1	37	49.3	0.014	
		AA	21	29.6	32	42.7		
	Allelic model	G	68	47.9	49	32.7	0.008	0.528 (0.329 – 0.848)
		A	74	52.1	101	67.3	Ref	
rs11314476		GG	05	07.0	02	02.7		
	Additive model	GA	26	36.6	22	29.3	0.248	
		AA	40	56.4	51	68.0		
	Allelic model	G	36	25.4	26	17.3	0.096	0.617 (0.350 – 1.090)
		A	106	74.6	124	82.7	Ref	

the distribution of the rs1131476 polymorphism were observed between the two study groups under both the additive (p=0.248), and allelic models (OR 0.617 [95% CI 0.350-1.090], p=0.096), suggesting that this missense mutation was not associated with COVID-19 severity in Moroccans. The comparison of the occurrence of these polymorphisms in their respective haplotype block between the two groups studied is shown in Table 4. The three selected SNPs formed only three haplotypes GGG, GAC and AAC. The two haplotypes GGG, and GAC were common in Asymptomatic/Mild versus Moderate/Severe patients and associated compared to the risk AAC haplotype with OR 0.529 [95% CI 0.285 – 0.973], p=0.034 and OR 0.527 [95% CI 0.028 – 0.509], p=0.041 respectively. These two haplotypes thus confer protection against severe COVID compared to the risk haplotype AAC in patients of

Tables 4. The comparison of the haplotype distribution consisting of rs10774671, rs1131462 and rs1051042 between the asymptomatic/mild group versus moderate/severe group

		Asymptomatic/Mild (N= 71)		Moderate /Severe (N = 75)		OR (95% CI)	
	\overline{N}	%	\overline{N}	%			
Haplotype							
GGG	36	25.4	26	17.3	0.034	0.529 (0.285 – 0.973)	
GAC	32	22.5	23	15.3	0.041	0.527 (0.028 – 0.509)	
AAC	74	52.1	101	67.4	Ref		

Moroccan origin.

it is made available direct a CO B1 4.0 international licen

Distribution of *OAS1* haplotypes in Berbers

Among the 80 males in our cohort of SARS-CoV-2-positive individuals, 41 were positive and 39 were negative for the E-M81 marker. The distribution of the three haplotypes studied GGG, GAC and AAC in these two groups, as well as that of 29 males with Parkinson's disease carrying the *LRRK2* G2019S mutation whose Berber origin has been established for both paternal and maternal lineages [20] were presented in Fig 3. The results showed that the prevalence of the African GAC haplotype in males with the E-M81 marker represented only 8.5% and was lower than that of males negative for this marker with 25.7%. Furthermore, this GAC haplotype was completely absent in males whose Berber origin concerned both the maternal and paternal lineages. The prevalence of both GGG and AAC haplotypes in these pure Berber males is close to that of European ancestry.

Fig 3. Frequencies of the three haplotypes consisting of the three OAS1 SNPs studied in 39

males negative and 41 males positive for E-M81 marker, all positive for SARS-CoV-2, and 29

males LRRK2 G2019S carriers whose Berber origin has been established for both paternal and

maternal lineages.

Discussion

The clinical presentation of COVID-19 following SARS-CoV-2 infection has shown high interindividual variability, ranging from asymptomatic to death, which is partly due to genetic factors. The chr12q24.13 region containing the *OAS* gene cluster was recently reported to be strongly associated with COVID-19

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

severity and mortality [4], and the rs10774671 splice variant was confirmed to be the functionally critical variant of this chromosomal region that influences the outcomes of SARS-CoV-2 infection [7, 8]. Indeed, the *OASI* rs10774671-G allele has been shown to increase levels of the p46 isoform and thus the circulating levels of OAS1 protein that were strongly associated with reduced risks of severe COVID-19 [5]. This protective G allele represents about 35% of individuals of European ancestry and was found on a haplotype inherited from the Neanderthal, and it represents 64% of the African population independently of this Neanderthal-derived haplotype [6]. To our knowledge, no data currently exist on the prevalence of *OAS* gene cluster variants in the North African population, which by its geographical position in the African continent could give relevant information on how this G allele at rs10774671 was inherited from the ancestral population common to both modern humans and Neanderthals. Our study thus presents a first insight into this chromosomal region in the Moroccan population, which is culturally, historically, and anthropologically similar to the other neighboring countries of the North African subcontinent. We showed that the frequencies of *OAS* cluster SNPs in Moroccans were close to the MAF of the 1000 genome project, where the *OAS1* rs10774671-G allele represented 40.4%. However, analyzing the haplotypes consisting of three *OAS1* variants that captured the Neanderthal haplotype showed that the rs10774671-G allele was found equally on both the Neanderthal GGG haplotype and the African GAC haplotype. This distribution seems different from

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

the European population where the G allele was mostly found at 35% in the Neanderthal haplotype, and from the African population where it was mostly found at 64% in a specific African haplotype, as reported before [6-8]. The study of these 3 selected SNPs in a series of 146 SARS-CoV-2 positive individuals of Moroccan origin less than 65 years of age showed that only the splice variant rs10774671 presents a significant association with the severity of COVID-19. Both the AA genotype and the A allele were predictive of severe COVID-19 disease, supporting literature findings that this is the only variant of this locus influencing COVID-19 outcomes [7, 8]. However, even though the prevalence of the protective allele *OAS1* rs10774671-G in the Moroccan population was close to that of Europeans, the severity and mortality caused by SARS-CoV-2 infection are much higher in individuals of European ancestry, even leading to a reduction in life expectancy [21]. This suggests that other genetic factors as well as general health factors and conditions, all interacting in complex ways, could be differentially involved between the two populations and remain to be discovered. Furthermore, both the Neanderthal GGG and African GAC haplotypes, containing the rs10774671-G allele were shown to be protective against severe COVID-19. Overall, in the 146 individuals positive for SARS-CoV-2, the frequency of the G allele and of the two GGG and GAC haplotypes were consistent with those obtained in the control cohort of our WES database, thus confirming the equal prevalence of around 20% for each of the two Neanderthal

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

and African haplotypes in the present-day Moroccans. The presence of the African haplotype could certainly be due to a recent admixture with sub-Saharan African populations, while the chronology of the presence of the Neanderthal haplotype in this population would be difficult to determine precisely. The Moroccan population is known to be a heterogeneous population having received influences from the south, north, and east, and whose ancient origin was essentially indigenous Berber. To provide elements of answers to the hypothesis of the origin of the Neanderthal Haplotype in North Africa, the distribution of the three haplotypes was compared in our series of SARS-CoV-2 positive individuals between males with and without the marker E-M81, known to be the specific male lineage of autochthonous Berbers of North Africa. The frequencies of the African GAC haplotype decreased to 8.5% in favor of the Neanderthal GGG haplotype which increased to 29.3% in males with the E-M81 marker compared to males without this marker at a frequency of 23% and 25.7% respectively. GAC haplotypes in males with the E-M81 marker are likely derived from maternal lineage. Surprisingly, the African GAC haplotype was completely absent in Berber males from both paternal and maternal lineages, and whose frequencies of the two remaining haplotypes GGG and AAC were similar to those of European ancestry. These results provide evidence for the presence of the Neanderthal protective haplotype among Berbers who are the ancient indigenous inhabitants of North Africa over the last 10,000 years. However, the question that remains to be asked

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

is whether this haplotype was imported to North Africa from the "back to Africa" migration or exported to Europe and Asia by the earlier "out of Africa" one. Several recent pieces of scientific evidence lean towards the second scenario. First, it has been reported that present-day North Africans share a majority of their ancestry with Europeans and West Asians but not with sub-Saharan Africans [22-24]. Along the same lines and in a slightly earlier period, the genetic study of human fossils from the Taforalt region dating back 15,000 years excluded gene flow from Southern Europe into northern Africa, as well as a genetic affinity with early Holocene Near Easterners, suggesting a late Pleistocene connection between North Africa and the Near East [25]. However, due to the absence in this region from ancient genomic data at a similar time, the authors could not define the epicenter or the direction of this connection. The study of the G2019S mutation of the *LRRK2* gene, a founder-effect mutation found in the haplotype 1 identified worldwide but with varying prevalence, was previously determined to originate from a Near-Eastern founder at least 4000 years ago and reintroduced by recurrent gene flow to European and North-African populations [26]. Using uniparental markers, we showed that the mutation arose in a Berber founder and its epicenter was indeed in North Africa, where the prevalence was the highest with 40%, and the gene flow by migration took place in the opposite direction [20]. In the same way, the site of Jebel Irhoud located in Morocco has provided valuable information missing in the puzzle of the history of hominids and in particular their

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

first exit from Africa to other continents. Irhoud hominids were originally considered as North African H. sapiens interbred with Neanderthals, an African form of Neanderthals, or a North African archaic population [27]. Recently, Hublin et al. [28] thermoluminescently dated the Irhoud fossils to 315,000 years ago, making Jebel Irhoud the oldest African hominid site with features of anatomically modern humans and more primitive cranial morphology. Phylogenetic modeling of cranial morphology showed phenotypic affinities of Irhoud fossils with both Neanderthals and early *H. sapiens* suggesting that they have been introgressed into Neanderthals at the end of the Middle Pleistocene contributing to the evolution of the Neanderthals [29]. Finally, we performed a whole genome sequencing of only three present-day Moroccans and identified over 200,000 SNV absent from 1000G and gnomAD databases, suggesting that the Moroccan population would have more genetic variability and therefore would be older than the European population. Principal components analysis showed that Moroccan genomes form a distinct population and placed them between European and African 1000G populations [30]. Sánchez-Quinto et al. [31] analyzed 780,000 SNPs in individuals from different locations in North Africa including Morocco and showed that North African populations have a significant excess of derived alleles shared with Neanderthals, whereas Sub-Saharan populations are not affected by this admixture event. The authors also showed that the Neanderthal's genetic signal was higher in populations with a local, pre-Neolithic North African ancestry, confirming that

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

this detected ancient admixture is not due to recent Near Eastern or European migrations. Furthermore, the first discovered Neanderthal fossil was at the Jbel Irhoud site [32], where Jean-Jacques Hublin et al. [28] dated the fossils found at 300,000 years old, that are accompanied by a Mousterian-type lithic industry, a lithic culture that has long been associated only with Neanderthals in Eurasia. Lithic data (Mousterians) have been reported long before this, and the oldest lithic remains discovered in Morocco belong to the Acheulean and are dated to around 1.3 million years [33, 34]. These data therefore constitute genomic, fossil and lithic evidence of the existence of Neanderthals in Morocco and their local contributions to anatomically modern humans, reinforcing the idea of a local introgression of the OASI rs10774671-G allele. Admittedly, Africa is the cradle of humanity, but the evolution of the hominid ancestors of *Homo Sapiens* did not occur in a linear way within this continent, but rather, through a focus dictated by severe geographical and climatic conditions. Therefore, the evolution of hominids in North Africa, isolated to the south by a largely arid and desert region, would have been different from that of sub-Saharan Africa, and would probably be at the origin of the initial dispersal out of Africa. Their conquest of the other continents would have been possible via the Strait of Gibraltar during the Ice Age, and later along the Mediterranean via the Fertile Crescent. The answers to this scenario are most likely to be found in the whole genome sequencing of a large series of present-day individuals and also in hominid fossils from North Africa.

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

perpetuity.

It is made available under a CC-BY 4.0 International license. **Conclusion** The rs10774671-G allele of *OAS1* confers protection against severe COVID-19 in the Moroccan population. Surprisingly, this protective allele was found in the Neanderthal haplotype in Berbers, the indigenous people of North Africa suggesting that this subcontinent could be the stepping-stone for the passage of the hominids to other continents. **Supporting information** S1 Table. Demographic, COVID-19 phenotype, genotype and haplotype of 3 OAS1 SNP of 146 individuals positive for SARS-COV-2. (xlsx) S1 Table. Genotype of Y-M81 marker in males positive for SARS-COV-2. (xlsx) **Acknowledgments** We thank all the participants in this study, and 3billion® (Seoul, Korea) for providing part of the whole exome sequencing free of charge.

Author Contributions

- 449 **Conceptualization:** Ahmed Bouhouche.
- 450 Formal analysis: Rachid Razine.

448

460

463

464

- 451 **Data Curation:** Omar Askander, Elmostafa El Fahime, Ahmed Bouhouche.
- 452 Funding acquisition: Ahmed Bouhouche.
- **Investigation:** Chaimae Nebhani, Fatima-Zahra El Youssfi, Ahmed Bouhouche, Redouane 453
- 454 Abougal, Khalid Ennibi, Hakima Fares, Abbas Ermilo Haroun, Jihane Belayachi.
- Methodology: Ahmed Bouhouche. 455
- 456 Project administration: Ahmed Bouhouche.
- 457 **Supervision:** Ahmed Bouhouche.
- 458 Validation: Ahmed Bouhouche.
- 459 Writing – review & editing: Ahmed Bouhouche.

Data availability statement 461

All relevant data are within the manuscript and its Supporting Information files. 462

References

- 465 Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019
- (COVID-19): A literature review. J Infect Pub Health. 2020; 466 13:667-673.
- 467 https://doi.org/10.1016/j.jiph.2020.03.019
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients 468
- 469 with pneumonia in China, 2019. New Engl J Med. 2020; 382:727-733.
- 470 https://doi.org/10.1056/nejmoa2001017
- 471 3. Ranjan J, Ravindra A, Mishra B. Gender and genetic factors impacting COVID-19
- 472 severity. Family Med Prim Care. 2021; 10:3956-3963.
- https://doi.org/10.4103/jfmpc.jfmpc 769 21 473

- Pairo-Castineira E, Clohisey, S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic 474
- 475 of Nature. mechanisms critical illness in COVID-19. 2020; 591:92-98.
- 476 https://doi.org/10.1038/s41586-020-03065-y
- 477 Zhou S, Hill CS, Sarkar S, Tse LV, Woodburn BMD, Schinazi RF, et al. \(\beta\text{-d-N}\) 4-
- 478 hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic
- 479 Infect mammalian cells. Dis. 2021; 224:415-419. to J
- 480 https://doi.org/10.1093/infdis/jiab247
- 481 Zeberg H, Pääbo S. A genomic region associated with protection against severe COVID-
- 482 19 is inherited from Neandertals. Proc Natl AcaD Sci USA. 2021; 118:e2026309118.
- 483 https://doi.org/10.1073/pnas.2026309118
- Banday AR, Stanifer ML, Florez-Vargas O, Onabajo OO, Papenberg BW, Zahoor M et al. 484
- 485 Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-
- 486 19 hospitalization in patients of European and African ancestries. Nat genet. 2022;
- 487 54:1103-1116. https://doi.org/10.1038/s41588-022-01113-z
- 488 Huffman JE, Butler-Laporte G, Khan A, Pairo-Castineira E, Drivas TG, Peloso GM, et al.
- 489 Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. Nat
- 490 genet. 2022; 54:125-127. https://doi.org/10.1038/s41588-021-00996-8
- 491 9. Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, et al. Genetic variation
- 492 in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS pathogens.
- 493 2009. 5:e1000321. https://doi.org/10.1371/journal.ppat.1000321
- 494 10. O'Brien M, Lonergan R, Costelloe L, O'Rourke K, Fletcher JM, Kinsella K, et al. OAS1:
- 495 a multiple sclerosis susceptibility gene that influences disease severity. Neurology. 2010;
- 496 75:411-418. https://doi.org/10.1212/wnl.0b013e3181ebdd2b
- 497 11. Mandal S, Abebe F, Chaudhary J. 2'-5' oligoadenylate synthetase 1 polymorphism is
- 498 associated Cancer. 2011; 117:5509-5518. with prostate cancer.
- 499 https://doi.org/10.1002/cncr.26219
- 12. Sams AJ, Dumaine A, Nédélec Y, Yotova V, Alfieri C, Tanner JE, et al. Adaptively 500
- 501 introgressed Neandertal haplotype at the OAS locus functionally impacts innate immune
- 502 responses in humans. Genome Biol. 2016; 17:246. https://doi.org/10.1186/s13059-016-
- 503 1098-6
- 13. Liu X, Xing H, Gao W, Yu D, Zhao Y, Shi X, et al. A functional variant in the OAS1 gene 504
- 505 is associated with Sjögren's syndrome complicated with HBV infection. Sci Rep. 2017;
- 506 7:17571. https://doi.org/10.1038/s41598-017-17931-9

- 14. Wu S, Wang Y, Chen G, Zhang M, Wang M, He JQ. 2'-5'-Oligoadenylate synthetase 1 507
- 508 polymorphisms are associated with tuberculosis: a case-control study. BMC Pulm Med.
- 509 2018; 18:180. https://doi.org/10.1186/s12890-018-0746-x
- 510 15. Choi UY, Kang JS, Hwang YS, Kim YJ, Oligoadenylate synthase-like (OASL) proteins:
- 511 dual functions and associations with diseases. Exp Mol Med. 2015; 47:e144.
- 512 https://doi.org/10.1038/emm.2014.110
- 16. Wickenhagen A, Sugrue E, Lytras S, Kuchi S, Noerenberg M, Turnbull ML, et al. A 513
- 514 prenylated dsRNA sensor protects against severe COVID-19. Science. 2021;
- 515 374:eabj3624. https://doi.org/10.1126/science.abj3624
- 516 17. Kjær KH, Pahus J, Hansen MF, Poulsen JB, Christensen EI, Justesen J, et al. Mitochondrial
- localization of the OAS1 p46 isoform associated with a common single nucleotide 517
- 518 polymorphism. BMC cell biol. 2014; 15:33. https://doi.org/10.1186/1471-2121-15-33
- 519 **18.** Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-α2b Treatment
- 520 for COVID-19. Front Immunol. 2020; 11:1061. https://doi.10.3389/fimmu.2020.01061
- 521 19. Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from
- 522 Neanderthals. Nature. 2020; 587:610–612. https://doi.org/10.1038/s41586-020-2818-3
- 523 20. Ben El Haj R, Salmi A, Regragui W, Moussa A, Bouslam N, Tibar H, et al. Evidence for
- 524 prehistoric origins of the G2019S mutation in the North African Berber population. PLoS
- 525 One. 2017; 12:e0181335. https://doi.org/10.1371/journal.pone.0181335
- 21. Schöley J, Aburto JM, Kashnitsky I, Kniffka MS., Zhang L, Jaadla H, et al. Life expectancy 526
- 527 since COVID-19. Nat Hum Behav. 2022; 6(12):1649-1659. changes
- 528 https://doi.org/10.1038/s41562-022-01450-3
- 529 22. Botigué LR, Henn BM, Gravel S, Maples BK, Gignoux CR, Corona E, et al. Gene flow
- 530 from North Africa contributes to differential human genetic diversity in southern Europe.
- 531 Proc Natl AcaD Sci USA. 2013; 110:11791-11796. https://doi.10.1073/pnas.1306223110
- 23. Schuenemann VJ, Peltzer A, Welte B, van Pelt WP, Molak M, Wang CC, et al. Ancient 532
- 533 Egyptian mummy genomes suggest an increase of Sub-Saharan African ancestry in post-
- 534 Roman periods. Nat Commun. 2017; 8:15694. https://doi.org/10.1038/ncomms15694
- 535 24. Pakstis AJ, Gurkan C, Dogan M, Balkaya HE, Dogan S, Neophytou PI, et al. Genetic
- 536 relationships of European, Mediterranean, and SW Asian populations using a panel of 55
- 537 AISNPs. Eur J Hum Genet. 2019; 27:1885-1893. https://doi.10.1038/s41431-019-0466-6
- 25. van de Loosdrecht M, Bouzouggar A, Humphrey L, Posth C, Barton N, Aximu-Petri A, et 538
- 539 al. Pleistocene North African genomes link near Eastern and sub-Saharan African human
- 540 populations. Science. 2018; 360, 548–552. https://doi.org/10.1126/science.aar8380

- 26. Lesage S, Patin E, Condroyer C, Leutenegger AL, Lohmann E, Giladi N, et al. Parkinson's 541
- 542 disease-related LRRK2 G2019S mutation results from independent mutational events in
- humans. Hum Mol Genet. 2010; 19:1998-2004. https://doi.org/10.1093/hmg/ddq081 543
- 544 27. Bruner E, Pearson O, Neurocranial evolution in modern humans: the case of Jebel Irhoud
- 545 1. Anthropol Sci. 2013; 121:31-41. https://doi.org/10.1537/ase.120927
- 546 28. Hublin JJ, Ben-Ncer A, Bailey SE, Freidline SE, Neubauer, Skinner MM, et al. New fossils
- 547 from Jebel Irhoud, Morocco and the pan-African origin of Homo sapiens. Nature. 2017;
- 548 546:289–292. https://doi.org/10.1038/nature22336
- 549 29. Mounier A, Mirazón LM. Deciphering African late middle Pleistocene hominin diversity
- 550 and the origin of our species. Nat Commun. 2019; 10:3406.
- https://doi.org/10.1038/s41467-019-11213-w 551
- 552 30. Crooks L, Cooper-Knock J, Heath PR, Bouhouche A, Elfahime M, Azzouz M, et al.
- 553 Identification of single nucleotide variants in the Moroccan population by whole-genome
- 554 sequencing. BMC Genet. 2020; 21:111. https://doi.org/10.1186/s12863-020-00917-4
- 555 31. Sánchez-Quinto F, Botigué LR, Civit S, Arenas C, Avila-Arcos MC, Bustamante CD, et
- 556 al. North African populations carry the signature of admixture with Neandertals. PLoS
- 557 One. 2012; 7:e47765. https://doi.10.1371/journal.pone.0047765
- 558 32. Arambourg C. Découverte au Maroc d'un crâne de Néanderthalien. Bulletin de la Société
- 559 Préhistorique Française. 1962; 59-7-8:513-514.
- 33. Mohib A, Raynal JP, Gallotti R, Daujeard C, El Graoui M, Fernandes P, et al. Forty Years 560
- 561 of Research at Casablanca (Morocco): New Insights in the Early/Middle Pleistocene
- 562 Archaeology and Geology. Hespéris-Tamuda, Eléments d'Archéologie préhistorique
- 563 marocaine. 2019; LIV (3):25-56. hal-03067997
- 34. Gallotti R, Muttoni G, Lefèvre D, Degeai JP, Geraads D, Zerboni A, et al. First high 564
- 565 resolution chronostratigraphy for the early North African Acheulean at Casablanca
- 566 (Morocco). Sci Rep. 2021; 11:15340. https://doi.10.1038/s41598-021-94695-3




Figure 1




Figure 2




Figure 3